

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

October 29, 2020

Adrian Gottschalk Chief Executive Officer Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02142

**Re:** Foghorn Therapeutics

**Registration Statement on Form S-1** 

Exhibit No. 10.3

Filed October 19, 2020 File No. 333-249264

Dear Mr. Gottschalk:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance

cc: Rachel Phillips, Esq.